Confusing Alzheimer’s Data Leaves Big Decision in FDA Hands

(Bloomberg) -- Biogen Inc. unveiled the most detailed data yet on the Alzheimer’s drug that it shelved and then brought back in one of the most head-spinning episodes in biotechnology history.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.